Post-approval studies (Phase 4)Study completedNCT00402233
What this trial is testing
A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients
Who this might be right for
Parkinson Disease
Boehringer Ingelheim 312